Gang Zhan1, Hui Jiang1, Rui Yang1, Kai Yang1. 1. Department of General Surgery, Central Theater General Hospital (Hankou Hospital) Wuhan 430010, Hubei, China.
Abstract
OBJECTIVE: To quantify the miR-122 and miR-197 expression levels in liver cancer (LC) patients before and after chemotherapy and to determine their prognostic implications. METHODS: The present study included 169 patients with LC who were admitted to our hospital from January 2005 to December 2010. The miR-122 and miR-197 expression levels in the patients' cancerous and adjacent tissues were quantified, and their peripheral blood levels before and after chemotherapy were analyzed, as well as their prognostic implications. RESULTS: The miR-122 and miR-197 levels in the LC tissues were lower than they were in the adjacent tissues, and they increased in the peripheral blood after chemotherapy. Higher miR-122 and miR-197 expression levels were observed in the LC tissues of sorafenib-sensitive patients. ROC curves demonstrated that miR-122 and miR-197 are predictive markers for the therapeutic effect of sorafenib. As shown by a K-M survival curve and a log-rank test, low miR-122 and miR-197 levels are responsible for low 5-year patient survival rates. Moreover, a univariate Cox analysis uncovered the association between the 5-year survival and the miR-122 and miR-197 expression levels, the size and number of tumors, vascular invasion, and TNM and BCLC staging. Also, a multivariate Cox analysis indicated that the independent risk factors for 5-year survival in LC included the miR-122 and miR-197 levels, the number of tumors, vascular invasion, and TNM and BCLC staging. CONCLUSION: miR-122 and miR-197 expression levels can predict LC patient responses to sorafenib chemotherapy, and their levels increase after chemotherapy. Moreover, decreased miR-122 and miR-197 levels are independent risk factors for LC progression. AJTR
OBJECTIVE: To quantify the miR-122 and miR-197 expression levels in liver cancer (LC) patients before and after chemotherapy and to determine their prognostic implications. METHODS: The present study included 169 patients with LC who were admitted to our hospital from January 2005 to December 2010. The miR-122 and miR-197 expression levels in the patients' cancerous and adjacent tissues were quantified, and their peripheral blood levels before and after chemotherapy were analyzed, as well as their prognostic implications. RESULTS: The miR-122 and miR-197 levels in the LC tissues were lower than they were in the adjacent tissues, and they increased in the peripheral blood after chemotherapy. Higher miR-122 and miR-197 expression levels were observed in the LC tissues of sorafenib-sensitive patients. ROC curves demonstrated that miR-122 and miR-197 are predictive markers for the therapeutic effect of sorafenib. As shown by a K-M survival curve and a log-rank test, low miR-122 and miR-197 levels are responsible for low 5-year patient survival rates. Moreover, a univariate Cox analysis uncovered the association between the 5-year survival and the miR-122 and miR-197 expression levels, the size and number of tumors, vascular invasion, and TNM and BCLC staging. Also, a multivariate Cox analysis indicated that the independent risk factors for 5-year survival in LC included the miR-122 and miR-197 levels, the number of tumors, vascular invasion, and TNM and BCLC staging. CONCLUSION:miR-122 and miR-197 expression levels can predict LC patient responses to sorafenib chemotherapy, and their levels increase after chemotherapy. Moreover, decreased miR-122 and miR-197 levels are independent risk factors for LC progression. AJTR
Authors: Tanyalak Parimon; Rena Brauer; Saundra Y Schlesinger; Ting Xie; Dianhua Jiang; Lingyin Ge; Ying Huang; Timothy P Birkland; William C Parks; David M Habiel; Cory M Hogaboam; Sina A Gharib; Nan Deng; Zhenqui Liu; Peter Chen Journal: Am J Pathol Date: 2018-01-31 Impact factor: 4.307